Rigel Pharmaceuticals entered into a collaboration and license agreement with Kissei Pharmaceutical, granting Kissei exclusive rights to develop and commercialize olutasidenib in Japan, Korea, and Taiwan, with Rigel receiving an upfront payment of $10 million and potential milestone payments totaling $152.5 million.